Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Government Report Outlines Costs, Savings Of Major Regs

Executive Summary

The US HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.

You may also be interested in...



Consent Requirement Change Could Be Boon For Minimal-Risk Studies

US FDA has issued a temporary guidance to allow researchers to conduct "minimal-risk" clinical studies without consent and harmonize the agency's policy with the federal Common Rule for human subject research. The guideline implements a provision in the 21st Century Cures Act.

Q&A: Device Industry Attorney Talks Mass Tort Strategy, Pitfalls

Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit.

Lawmakers Press CMS To Enact MCIT Breakthrough Device Coverage Rule

The Medicare rule, which was delayed by 60 days under a broader regulatory freeze, is seen as critical to the reimbursement of innovative devices.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel